Kilitch Drugs (India) Ltd. – Company Report
1. Company Overview
Kilitch Drugs (India) Ltd., established in 1978 and incorporated in 1992, is a Mumbai-based pharmaceutical manufacturing company specializing in injectables and sterile dosage forms. The company operates modern manufacturing units in Maharashtra and Ethiopia, catering to a wide global market including India, Africa, Southeast Asia, and the Middle East. Known for its robust presence in cephalosporins, sterile formulations, and contract manufacturing, Kilitch continues to scale its export-led model. The company is publicly listed on the BSE and NSE with a market capitalization of ₹640–790 crore as of July 2025.
- Incorporated: 1992 (Operations since 1978)
- Headquarters: Mumbai, Maharashtra, India
- Listed On: BSE, NSE
- Employee Strength: ~160
- Manufacturing Presence: India and Ethiopia
- Core Focus: Injectables, cephalosporins, orals, nutraceuticals, and medical devices
2. Products and Services
Kilitch Drugs operates a diversified product and service portfolio across key healthcare domains:
Sterile Injectables:
- Liquid ampoules and vials
- Small- and large-volume injectables
- Cephalosporin formulations
Oral Dosage Forms:
- Tablets, capsules, dry syrups, oral powders, effervescent tablets
Nutritional and Adjunct Products:
- Multivitamin injectables, vitamin/mineral supplements, infusions
Medical Devices and Topicals:
- CE-certified adhesives (C-Seal) and surgical-grade products
Herbal and Personal Care:
- Creams, oils, and plant-based wellness products
Contract Manufacturing:
- Turnkey production for third-party pharmaceutical clients
Therapeutic Areas Covered:
- Gastroenterology, anti-malarials, cardiovascular, antibiotics, anti-diabetics, and veterinary healthcare
3. Recent News and Financial Performance
Key Highlights:
- Ethiopia cephalosporin plant is now fully operational, significantly boosting global export capabilities.
- Rights issue in July 2025 to support capacity expansion and product diversification.
- New Khopoli plant under development to meet advanced international regulatory standards.
- Continued R&D efforts and pipeline growth in sterile and niche formulations.
Subsidiary Achievement:
- February 27, 2024: Kilitch Drug (India) Limited has announced that its subsidiary Kilitch Estro Biotech PLC (Ethiopia) secured a USD 9.13 million (₹76 crore) government tender from the Ethiopian Pharmaceutical Supply Service, highlighting strong traction in African markets.
- July 3, 2025: Mumbai-based pharma company Kilitch Drugs (India) Ltd. is aiming to cross ₹1,000 crore in revenue within the next 3 to 4 years, driven by its upcoming Khopoli manufacturing facility and a strong presence in African and regulated markets. November 14, 2025: The company completed a rights issue, raising ₹4,992.51 lakhs by issuing 13,98,463 equity shares at ₹357 per share. The funds are primarily for capital expenditure on their Greenfield Project in Pen.
4. Financial Performance (FY2025)
| Metric | FY2025 Value |
|---|---|
| Total Revenue | ₹198 crore |
| Net Profit | ₹24.9 crore |
| EPS | ₹15.26 |
| Net Profit Margin | 12% |
| ROE | 14.2% |